27306062|t|Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response
27306062|a|Individual response to interferon beta (IFN-β) 1a treatment is heterogeneous in multiple sclerosis (MS). Our objective was to find a connection between serum levels of interleukin (IL)-10, IL-17 and transforming growth factor beta (TGF-β)1 in MS patients treated with IFN-β in order to identify the nonresponders (NR). We included in the study 32 healthy subjects and 32 MS patients: 10 naive, 10 early treated and 12 late treated with INF-β1a. Serum determination of cytokines and brain MRI were performed at the beginning of the study, after 6 and 12 months. Rio score was calculated at the end of the study. MS patients had initially a significant higher level of IL-17 and a lower level of TGF-β1 compared to healthy subjects. IL-17 level in early treated patients was significantly lower compared to the naive and late treated groups. INF-β1a treatment significantly increased IL-10 and decreased IL-17 levels. Initial low levels of IL-10 were associated with an increase in physical disability. IL-17 levels positively correlated with the number of relapses and MRI activity. Nine patients were NR to Avonex. Patients with a Rio score of 3 had higher initial levels of IL-17 and those with a Rio score of 0 had higher initial levels of IL-10 and TGF-β1. IFN-β1a decreased IL-17 and increased IL-10 seric levels; IL-17 significantly correlated with MS activity; TGF-β1 activity is titer-dependent, increased levels were associated with IL-17 inhibition; NR patients to IFN-β1a will have initial high IL-17 and low IL-10 and TGF-β seric levels.
27306062	0	10	Assessment	T052	C1516048
27306062	14	29	Interleukin-17A	T116,T192	C1705947
27306062	31	45	Interleukin-10	T116,T129	C0085295
27306062	50	82	Transforming Growth Factor-Beta1	T116,T121,T123	C1704256
27306062	83	88	Serum	T031	C0229671
27306062	89	95	Titers	T081	C0475208
27306062	99	108	Relapsing	T067	C0035020
27306062	109	118	Remitting	T079	C0439600
27306062	119	137	Multiple Sclerosis	T047	C0026769
27306062	138	146	Patients	T101	C0030705
27306062	147	154	Treated	T169	C1522326
27306062	160	166	Avonex	T116,T121,T129	C0594372
27306062	168	176	Possible	T033	C0332149
27306062	177	187	Biomarkers	T201	C0005516
27306062	192	210	Treatment Response	T201	C0521982
27306062	211	221	Individual	T098	C0237401
27306062	222	230	response	T201	C0521982
27306062	234	260	interferon beta (IFN-β) 1a	T116,T121,T129	C0254119
27306062	261	270	treatment	T169	C1522326
27306062	274	287	heterogeneous	T080	C0019409
27306062	291	309	multiple sclerosis	T047	C0026769
27306062	311	313	MS	T047	C0026769
27306062	320	329	objective	T170	C0018017
27306062	344	354	connection	T082	C0449379
27306062	363	368	serum	T031	C0229671
27306062	369	375	levels	T080	C0441889
27306062	379	398	interleukin (IL)-10	T116,T129	C0085295
27306062	400	405	IL-17	T116,T129	C0384648
27306062	410	450	transforming growth factor beta (TGF-β)1	T116,T121,T123	C1704256
27306062	454	456	MS	T047	C0026769
27306062	457	465	patients	T101	C0030705
27306062	466	473	treated	T169	C1522326
27306062	479	484	IFN-β	T116,T121,T129	C0015980
27306062	497	505	identify	T033	C0243095
27306062	510	523	nonresponders	T033	C0243095
27306062	525	527	NR	T033	C0243095
27306062	549	554	study	T062	C0008972
27306062	558	574	healthy subjects	T098	C1708335
27306062	582	584	MS	T047	C0026769
27306062	585	593	patients	T101	C0030705
27306062	598	603	naive	T077	C2986417
27306062	608	613	early	T079	C1279919
27306062	614	621	treated	T169	C1522326
27306062	634	641	treated	T169	C1522326
27306062	647	654	INF-β1a	T116,T121,T129	C0254119
27306062	656	661	Serum	T031	C0229671
27306062	662	675	determination	T059	C1148554
27306062	679	688	cytokines	T116,T129	C0079189
27306062	693	702	brain MRI	T060	C0412675
27306062	708	717	performed	T169	C0884358
27306062	725	734	beginning	T079	C0439659
27306062	742	747	study	T062	C0008972
27306062	764	770	months	T079	C0439231
27306062	772	781	Rio score	T081	C0449820
27306062	786	796	calculated	T052	C1441506
27306062	815	820	study	T062	C0008972
27306062	822	824	MS	T047	C0026769
27306062	825	833	patients	T101	C0030705
27306062	838	847	initially	T079	C0205265
27306062	850	868	significant higher	T081	C4055637
27306062	869	874	level	T080	C0441889
27306062	878	883	IL-17	T116,T129	C0384648
27306062	890	895	lower	T052	C2003888
27306062	896	901	level	T080	C0441889
27306062	905	911	TGF-β1	T116,T121,T123	C1704256
27306062	912	920	compared	T052	C1707455
27306062	924	940	healthy subjects	T098	C1708335
27306062	942	947	IL-17	T116,T129	C0384648
27306062	948	953	level	T080	C0441889
27306062	957	962	early	T079	C1279919
27306062	963	970	treated	T169	C1522326
27306062	971	979	patients	T101	C0030705
27306062	984	1003	significantly lower	T081	C4055638
27306062	1004	1012	compared	T052	C1707455
27306062	1030	1034	late	T079	C0205087
27306062	1035	1042	treated	T169	C1522326
27306062	1043	1049	groups	T098	C0687744
27306062	1051	1058	INF-β1a	T116,T121,T129	C0254119
27306062	1059	1068	treatment	T169	C1522326
27306062	1069	1092	significantly increased	T081	C0205217
27306062	1093	1098	IL-10	T116,T129	C0085295
27306062	1103	1112	decreased	T081	C0205216
27306062	1113	1118	IL-17	T116,T129	C0384648
27306062	1119	1125	levels	T080	C0441889
27306062	1127	1134	Initial	T079	C0205265
27306062	1135	1138	low	T080	C0205251
27306062	1139	1145	levels	T080	C0441889
27306062	1149	1154	IL-10	T116,T129	C0085295
27306062	1160	1175	associated with	T080	C0332281
27306062	1179	1187	increase	T169	C0442805
27306062	1191	1210	physical disability	T046	C0520817
27306062	1212	1217	IL-17	T116,T129	C0384648
27306062	1218	1224	levels	T080	C0441889
27306062	1225	1246	positively correlated	T080	C1707520
27306062	1256	1262	number	T081	C0237753
27306062	1266	1274	relapses	T067	C0035020
27306062	1279	1282	MRI	T060	C0024485
27306062	1283	1291	activity	T052	C0441655
27306062	1298	1306	patients	T101	C0030705
27306062	1312	1314	NR	T033	C0243095
27306062	1318	1324	Avonex	T116,T121,T129	C0594372
27306062	1326	1334	Patients	T101	C0030705
27306062	1342	1351	Rio score	T081	C0449820
27306062	1361	1367	higher	T080	C0205250
27306062	1368	1375	initial	T079	C0205265
27306062	1376	1382	levels	T080	C0441889
27306062	1386	1391	IL-17	T116,T129	C0384648
27306062	1409	1418	Rio score	T081	C0449820
27306062	1428	1434	higher	T080	C0205250
27306062	1435	1442	initial	T079	C0205265
27306062	1443	1449	levels	T080	C0441889
27306062	1453	1458	IL-10	T116,T129	C0085295
27306062	1463	1469	TGF-β1	T116,T121,T123	C1704256
27306062	1471	1478	IFN-β1a	T116,T121,T129	C0254119
27306062	1479	1488	decreased	T081	C0205216
27306062	1489	1494	IL-17	T116,T129	C0384648
27306062	1499	1508	increased	T081	C0205217
27306062	1509	1514	IL-10	T116,T129	C0085295
27306062	1515	1520	seric	T031	C0229671
27306062	1521	1527	levels	T080	C0441889
27306062	1529	1534	IL-17	T116,T129	C0384648
27306062	1535	1559	significantly correlated	T080	C1707520
27306062	1565	1567	MS	T047	C0026769
27306062	1568	1576	activity	T052	C0441655
27306062	1578	1584	TGF-β1	T116,T121,T123	C1704256
27306062	1585	1593	activity	T052	C0441655
27306062	1597	1612	titer-dependent	T080	C0851827
27306062	1614	1623	increased	T081	C0205217
27306062	1624	1630	levels	T080	C0441889
27306062	1636	1651	associated with	T080	C0332281
27306062	1652	1657	IL-17	T116,T129	C0384648
27306062	1658	1668	inhibition	T052	C3463820
27306062	1670	1672	NR	T033	C0243095
27306062	1673	1681	patients	T101	C0030705
27306062	1685	1692	IFN-β1a	T116,T121,T129	C0254119
27306062	1703	1710	initial	T079	C0205265
27306062	1711	1715	high	T080	C0205250
27306062	1716	1721	IL-17	T116,T129	C0384648
27306062	1726	1729	low	T080	C0205251
27306062	1730	1735	IL-10	T116,T129	C0085295
27306062	1740	1745	TGF-β	T116,T123	C0040690
27306062	1746	1751	seric	T031	C0229671
27306062	1752	1758	levels	T080	C0441889